IN2014CN00961A - - Google Patents
Info
- Publication number
- IN2014CN00961A IN2014CN00961A IN961CHN2014A IN2014CN00961A IN 2014CN00961 A IN2014CN00961 A IN 2014CN00961A IN 961CHN2014 A IN961CHN2014 A IN 961CHN2014A IN 2014CN00961 A IN2014CN00961 A IN 2014CN00961A
- Authority
- IN
- India
- Prior art keywords
- compounds
- intended
- lsd1
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Abstract
In one aspect the invention relates to substituted (E) N (1 phenylethylidene)benzohydrazide analogs derivatives thereof and related compounds which are useful as inhibitors of lysine specific histone demethylase including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161523801P | 2011-08-15 | 2011-08-15 | |
PCT/US2012/050948 WO2013025805A1 (en) | 2011-08-15 | 2012-08-15 | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN00961A true IN2014CN00961A (en) | 2015-04-10 |
Family
ID=47715455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN961CHN2014 IN2014CN00961A (en) | 2011-08-15 | 2012-08-15 |
Country Status (25)
Country | Link |
---|---|
US (2) | US8987335B2 (en) |
EP (1) | EP2744330B1 (en) |
JP (1) | JP6122006B2 (en) |
KR (1) | KR101983537B1 (en) |
CN (1) | CN103929960B (en) |
AU (1) | AU2012296639B2 (en) |
BR (1) | BR112014003382B1 (en) |
CA (1) | CA2843609C (en) |
CY (1) | CY1123345T1 (en) |
DK (1) | DK2744330T3 (en) |
EA (1) | EA026389B1 (en) |
ES (1) | ES2821548T3 (en) |
HK (1) | HK1200052A1 (en) |
HR (1) | HRP20201433T1 (en) |
HU (1) | HUE050962T2 (en) |
IL (1) | IL230728A (en) |
IN (1) | IN2014CN00961A (en) |
LT (1) | LT2744330T (en) |
MX (1) | MX356486B (en) |
PL (1) | PL2744330T3 (en) |
PT (1) | PT2744330T (en) |
SG (1) | SG2014009609A (en) |
SI (1) | SI2744330T1 (en) |
WO (1) | WO2013025805A1 (en) |
ZA (1) | ZA201400881B (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
BR112015007083A2 (en) | 2012-10-02 | 2017-07-04 | Epitherapeutics Aps | histone demethylase inhibitors |
AP2015008676A0 (en) * | 2013-02-27 | 2015-08-31 | Epitherapeutics Aps | Inhibitors of histone demethylases |
AU2014249050B2 (en) * | 2013-03-12 | 2017-10-05 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
SG10201710543PA (en) * | 2013-06-19 | 2018-02-27 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
US9670210B2 (en) | 2014-02-13 | 2017-06-06 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ME03580B (en) | 2014-02-13 | 2020-07-20 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US10807944B2 (en) | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
JP2017518312A (en) * | 2014-06-05 | 2017-07-06 | ユニバーシティ・オブ・カンザス | Malmelin analogs and methods of use in cancer treatment |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
CN106146361A (en) * | 2015-03-16 | 2016-11-23 | 四川大学 | Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
EP3429571A1 (en) | 2016-03-15 | 2019-01-23 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
EP3430015A1 (en) | 2016-03-16 | 2019-01-23 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
MA44725A (en) | 2016-04-22 | 2019-02-27 | Incyte Corp | LSD1 INHIBITOR FORMULATIONS |
EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
WO2018017589A1 (en) | 2016-07-19 | 2018-01-25 | The General Hospital Corporation | Compounds for targeting cancer stem cells |
WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
MA51507A (en) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | MARKERS FOR PERSONALIZED CANCER TREATMENT WITH LSD1 INHIBITORS |
CN106831489B (en) * | 2017-03-23 | 2018-04-17 | 郑州大学 | Tranylcypromine acylhydrazone, preparation method and applications |
BR112020000827A2 (en) | 2017-08-03 | 2020-07-21 | Oryzon Genomics, S.A. | methods of treating behavioral changes |
US10980777B2 (en) | 2017-08-18 | 2021-04-20 | Istituto Europeo Di Oncologia S.R.L. | Indole derivatives as histone demethylase inhibitors |
WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | Lsd1 inhibitors for the treatment and prevention of cardiomyopathies |
CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
CN109793742A (en) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | A kind of medical compounds application |
WO2020188089A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
CN109758442B (en) * | 2019-03-20 | 2021-08-17 | 武汉大学 | Application of diaryl hydrazide compound in preparation of anti-influenza virus medicine |
SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
WO2022020804A1 (en) * | 2020-07-24 | 2022-01-27 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
BR112023020554A2 (en) | 2021-04-08 | 2023-12-05 | Oryzon Genomics Sa | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF MYELOID CANCERS |
WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
CN116077661A (en) * | 2022-08-22 | 2023-05-09 | 沈阳药科大学 | Application of KDM1A inhibitor in preparation of medicine for treating DNMT3A gene deletion cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002252976A1 (en) | 2001-01-22 | 2002-09-19 | Arpida Ag | Hydrazones and their therapeutic use |
JP2002302472A (en) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | Maillard reaction inhibitor |
EP1649852A1 (en) | 2003-07-16 | 2006-04-26 | Institute of Medicinal Molecular Design, Inc. | Chromatosis remedies |
WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
TW200800145A (en) * | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
CA2626846A1 (en) | 2005-11-03 | 2007-05-18 | Redpoint Bio Corporation | Hydrazone derivatives and uses thereof |
WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
MX2009008243A (en) | 2007-02-02 | 2009-08-12 | Redpoint Bio Corp | Use of a trpm5 inhibitor to regulate insulin and glp-1 release. |
JP2010523579A (en) * | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | CFTR inhibitor compounds and their use |
EP2195029A2 (en) * | 2007-08-24 | 2010-06-16 | Oryzon Genomics SA | Treatment and prevention of neurodegenerative diseases |
AR070898A1 (en) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | ARILSULFONIL PIRAZOLIN CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS |
EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | Heparan sulfate inhibitors |
EP2376435A2 (en) * | 2009-01-14 | 2011-10-19 | Dow AgroSciences LLC | Synergistic fungicidal compositions including hydrazone derivatives and copper |
US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
-
2012
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/en unknown
- 2012-08-15 SI SI201231841T patent/SI2744330T1/en unknown
- 2012-08-15 PT PT128235405T patent/PT2744330T/en unknown
- 2012-08-15 EA EA201490453A patent/EA026389B1/en unknown
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 ES ES12823540T patent/ES2821548T3/en active Active
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/en active IP Right Grant
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/en active Active
- 2012-08-15 PL PL12823540T patent/PL2744330T3/en unknown
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/en unknown
- 2012-08-15 MX MX2014001842A patent/MX356486B/en active IP Right Grant
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/en active Active
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/en active Application Filing
- 2012-08-15 CA CA2843609A patent/CA2843609C/en active Active
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/en active
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/en active IP Right Grant
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/en active Active
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-01-15 HK HK15100490.8A patent/HK1200052A1/en unknown
- 2015-02-16 US US14/623,370 patent/US9555024B2/en active Active
-
2020
- 2020-09-08 HR HRP20201433TT patent/HRP20201433T1/en unknown
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN00961A (en) | ||
WO2014194280A3 (en) | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells | |
CY1122556T1 (en) | SUBSTITUTED N-PHENYLPYRIMIDINE-2-AMINE ANALOGS AS AXL KINASE INHIBITORS | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
WO2012118563A3 (en) | 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same | |
WO2014055928A3 (en) | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors | |
EA201890086A1 (en) | 1,4-substituted derivatives of piperidine | |
EA201691428A1 (en) | BICYCLIC HETEROCYCLIC DERIVATIVES AS IRAK4 INHIBITORS | |
WO2014055934A3 (en) | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors | |
AR084433A1 (en) | FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EA201391230A1 (en) | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | |
MX347982B (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels. | |
MX2013009393A (en) | Chroman - spirocyclic piperidine amides as modulators of ion channels. | |
CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
MX2013008902A (en) | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels. | |
MX2009013169A (en) | Benzamide mglur5 positive allosteric modulators and methods of making and using same. | |
MX350862B (en) | Piperidinyl naphthylacetic acids. | |
PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
ECSP14030538A (en) | BRIDGE HEAD CYCLIC ETHER DGAT1 INHIBITORS | |
PE20150224A1 (en) | NAMPT INHIBITORS | |
CL2013003484A1 (en) | Compounds derived from n- (4-morpholin-2-yl) phenyl) -1h-pyrazole- (3 or 5) -carboxamide or n- (4-piperidin-3-yl) phenyl) -1h-pyrazole- (3 or 5) -carboxamide related to receptors associated with taar1; preparation procedure; Pharmaceutical composition and use in the treatment and / or prophylaxis of diseases such as depression, bipolar disorder, Alzheimer's and Parkinson's, among others. | |
EA201490152A1 (en) | TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT | |
MD20160105A2 (en) | 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | |
WO2013006734A8 (en) | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity | |
EP2575461A4 (en) | Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators |